Amgen announced on Tuesday the submission of a supplemental Biologics License Application to the FDA for Blincyto, or blinatumomab, to include overall survival data from the phase 3 TOWER study, supporting the conversion of Blincyto's accelerated approval to full approval.
Bristol-Myers Squibb Canada Co. announced last Friday the company reached an agreement with the pan-Canadian Pharmaceutical Alliance for the immuno-oncology treatment Opdivo, or nivolumab, bringing patients with advanced, difficult-to-treat cancers closer to accessing a new treatment option.
Immunomedics Inc. entered into a global licensing agreement with Seattle Genetics Inc. to develop, fund, manufacture and commercialize IMMU-132, Immunomedics' proprietary solid tumor therapy candidate.
FDA approved the nivolumab (Opdivo) injection for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
GenomeDx Biosciences and Astellas announced a collaboration to apply genomic tumor profiling using GenomeDx's Decipher Classifier and Decipher GRID as a potential aid in identifying prostate cancer patients undergoing active surveillance who may benefit from treatment with enzalutamide (Xtandi).
MD Anderson Cancer Center and Guardant Health announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment.
Indivumed, GmbH and Regeneron Pharmaceuticals Inc. signed an agreement providing Regeneron with access to Indivumed's quality tissue sample and clinical and molecular data collection methods, to support the company's cancer research programs.
The Addario Lung Cancer Medical Institute, the Bonnie J. Addario Lung Cancer Foundation and Scancell Holdings PLC announced a collaboration to evaluate the use of Scancell's second innovative cancer vaccine, SCIB2, from its ImmunoBody platform to treat non-small cell lung cancer.
Perthera Inc. said Novartis will use Perthera's cancer patient network to identify breast and lung cancer patients for targeted therapy trials.
Benitec Biopharma Ltd. started work on two oncology pipeline programs after executing a research collaboration agreement with Nant Capital LLC.